Frontiers in oncology · 2026
Acute and late toxicity in prostate cancer patients treated with moderately vs ultra-hypofractionated radiotherapy.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cifuentes-Quin Javier, Garcia-Montañez Yiselle T, Hurtado-Ortiz Alexandra, Cruz Jhonatan, Lagares Luis Carlos, Olarte-Licht Luis A, Licht-Ardila Maricel, Manrique-Hernández Edgar Fabián
Аннотация
INTRODUCTION: Prostate cancer is the most frequently diagnosed male malignancy in Colombia. While modern radiotherapy techniques allow for hypofractionated schedules due to the low alpha/beta ratio of prostate adenocarcinoma, real-world comparative data between moderate and ultra-hypofractionation in Latin American settings remain limited.
OBJECTIVE: To compare acute and early late toxicity in patients with prostate cancer treated with moderately hypofractionated radiotherapy versus those treated with ultra-hypofractionated regimen.
METHODS: A comparative historical cohort study was conducted at a Colombian oncology center between 2018 and 2025. A total of 229 patients with non-metastatic prostate cancer (T1-T4) were enrolled (MHRT: n=143; UHRT: n=86). Toxicity was graded using CTCAE criteria. Multivariable logistic regression was used to identify independent predictors of toxicity.
RESULTS: Acute toxicity was significantly higher in the MHRT group compared to the UHRT group (25.17% vs. 11.63%; p=0.013). Similarly, late toxicity was more frequent in the MHRT group (37.06% vs. 9.30%; p<0.001), with erectile dysfunction as the most common late event. Multivariable analysis showed that UHRT was independently associated with lower odds of acute toxicity (aOR 0.44; 95% CI 0.19-0.99; p=0.048).
CONCLUSION: UHRT showed a generally favorable safety profile, with trends toward lower acute and late toxicity compared to MHRT. In middle-income settings such as Colombia, UHRT may offer a practical approach to enhance treatment efficiency and patient access, while maintaining acceptable clinical outcomes.
OBJECTIVE: To compare acute and early late toxicity in patients with prostate cancer treated with moderately hypofractionated radiotherapy versus those treated with ultra-hypofractionated regimen.
METHODS: A comparative historical cohort study was conducted at a Colombian oncology center between 2018 and 2025. A total of 229 patients with non-metastatic prostate cancer (T1-T4) were enrolled (MHRT: n=143; UHRT: n=86). Toxicity was graded using CTCAE criteria. Multivariable logistic regression was used to identify independent predictors of toxicity.
RESULTS: Acute toxicity was significantly higher in the MHRT group compared to the UHRT group (25.17% vs. 11.63%; p=0.013). Similarly, late toxicity was more frequent in the MHRT group (37.06% vs. 9.30%; p<0.001), with erectile dysfunction as the most common late event. Multivariable analysis showed that UHRT was independently associated with lower odds of acute toxicity (aOR 0.44; 95% CI 0.19-0.99; p=0.048).
CONCLUSION: UHRT showed a generally favorable safety profile, with trends toward lower acute and late toxicity compared to MHRT. In middle-income settings such as Colombia, UHRT may offer a practical approach to enhance treatment efficiency and patient access, while maintaining acceptable clinical outcomes.